James D. Ahlgren, MD
George Washington University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James D. Ahlgren, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00002664 · Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal CancerJames Ahlgren · withdrawn · Colorectal Cancer · study chair
- Ph2NCT00003622 · Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone TherapyJames Ahlgren · withdrawn · Prostate Cancer · study chair
- Ph2NCT00003865 · Toremifene in Treating Patients With Ovarian CancerGeorge Washington University · withdrawn · Ovarian Cancer · study chair
- Ph2NCT00002470 · Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid TumorsMid-Atlantic Oncology Program · completed · Gastrointestinal Carcinoid Tumor, Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 19 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.